Mesenchymal Stromal Cells (MSCs) are tissue homeostatic and immune modulatory cells that have shown beneficial effects in kidney diseases and transplantation. Perivascular Stromal Cells (PSCs) share characteristics with bone marrow MSCs (bmMSCs). However, they also possess, most likely due to local imprinting, tissue-specific properties and play a role in local tissue homeostasis. This tissue specificity may result in tissue specific repair, also within the human kidney. We previously showed that human kidney PSCs (kPSCs) have enhanced kidney epithelial wound healing whereas bmMSCs did not have this potential. Moreover, kPSCs can ameliorate kidney injury in vivo. Therefore, kPSCs constitute an interesting source for cell therapy, particularly for kidney diseases and renal transplantation. Here we show the detailed isolation and culture method for kPSCs from transplant-grade human kidneys based on whole-organ perfusion of digestive enzymes via the renal artery and enrichment for the perivascular marker NG2. In this way, large cell quantities can be obtained that are suitable for cellular therapy.
Introduction
Mesenchymal Stromal Cells (MSCs) are immune modulatory cells that were originally isolated from the bone marrow. They are characterized by their spindle shaped morphology, ability to differentiate into fat, bone and cartilage, and plastic adherence. MSCs express the stromal markers CD73, CD90, CD105 while being negative for the markers CD31 and CD45 1, 2, 3 . MSCs are a promising candidate for cell therapy due to their tissue homeostatic and immunomodulatory capacities. bmMSCs are currently being studied in clinical trials for several diseases, including kidney diseases and kidney transplantation as reviewed elsewhere 4 .
Previously it was shown that perivascular cells from several different solid organs, including adipose tissue, placenta and skeletal muscle share characteristics with MSCs 9 . However, these cells also exhibit tissue-specific functions which can result in organotypic repair 10 . Human myocardial perivascular cells, for example, stimulated angiogenic responses after hypoxia and differentiated into cardiomyocytes, while perivascular cells isolated from other tissues did not show these potentials 11 . Perivascular stromal cells can also be isolated from the mouse 12, 13, 14 and human kidney 15, 16 . We extensively characterized kPSCs and compared these to bmMSCs. We found that kPSCs, similar to bmMSCs, have immunosuppressive capacities and can support vascular plexus formation. However, there are tissue specific differences between the cell types, as kPSCs showed an organotypic transcriptional expression signature, including the nephrogenic transcription factors HoxD10 and HoxD11. kPSCs, in contrast to bmMSCs, did not undergo myofibroblast transformation after stimulation with TGF-β and were unable to differentiate into adipocytes. Furthermore, kPSCs accelerated epithelial integrity in a kidney tubular epithelial wound scratch assay, a phenomenon which was not observed with bmMSCs. This enhanced wound repair was mediated through hepatocyte growth factor release. Moreover, kPSCs ameliorated kidney injury in a mouse model of acute kidney injury 15 . Therefore, kPSCs seem to have superior renal repair capacities and are an interesting new source for cell therapy in kidney diseases.
In order to be able to use kPSCs for cell therapy purposes, kPSCs should be isolated in a clinical grade manner with clinical grade enzymes and protocols. Moreover, to be able to treat several patients with kPSCs from 1 donor, sufficient cell numbers should be obtained. Here we show in detail, the clinical grade isolation procedure of kPSCs from whole transplant grade kidneys, yielding sufficient numbers of cells to be used for clinical cellular therapy.
Protocol
The local medical ethical committee and ethical advisory board of the European consortium (STELLAR) approved the research and collection of human transplant grade kidneys discarded mainly for surgical reasons. Research consent was given for all kidneys. 
Preparations for Cell Harvest

Kidney Cell Isolation
1. Preparation of the kidney.
1. Remove the kidney from the double sterile bags and place on the sterile perfusion tray ( Figure 1B) . Remove the perirenal adipose tissue and kidney capsule with scissors and gentle tearing ( Figure 1C ) and identify the renal artery on the aortic patch as shown in Figure 1D . 2. Cannulate the renal artery with the accessory spike, fix with a sterilized tie-rip, and attach to the pump tube end with the Luer connector while the pump is on. If the tubes are not completely filled, first add more medium to the tray and flush tubes by starting the pump (Figure 1E -F) . Flush the kidney with plain medium via the pump with a flow of 100 mL/min.
2. Collagenase treatment and kidney cell isolation. 1. Add collagenase (20 mL, >2,000 U) and DNase (2.5 mL, 1 mg/mL) to the perfusion tray ( Figure 1G ). Turn the kidney from time to time gently by hand. Wait until the kidney becomes soft and the perfusion liquid becomes less transparent (approximately 30 -40 min). 2. Gently massage the kidney ( Figure 1H ) until a cell suspension is obtained ( Figure 1I) . Remove non-digested material and the spike in the renal artery.
Cell Culture of Crude Kidney Cells
1. Add approximately 1 mL of the cell suspension to 24 mL of alphaMEM 5% platelet lysates (cell culture medium) in a T175 cell culture flask ( Figure 1K ) and culture at 37 °C, 5% CO 2 . Remove the medium and cell debris after 2 d from the adherent cells and refresh the medium with 25 mL of cell culture medium. 2. Refresh the culture medium twice a week by removing half of the medium (12.5 mL) and adding fresh medium (12.5 mL) using aseptic techniques. 3. Culture until confluent (usually 5 -7 d) ( Figure 1L) . Remove the medium, wash twice with PBS and trypsinize the cells by adding 5 mL trypsin to each T175 flask for 5 min at 37 °C. Wash in culture medium and centrifuge at 490 x g for 5 min and remove the supernatant. ) and incubate. NOTE: Seed the cells in the following concentrations: <250,000 in a T25 flask, 250,000 -500,000 in a T75 flask, and 700,000 -800,000 in a T175 flask. After magnetic cell enrichment, a positive fraction of approximately 1 -2% is isolated. However, as this step is cell enrichment and not cell sorting, other cell types will be present in the culture (Figure 1N) . After several passages (usually around 4 -5), only a homogenous kPSC-population is present (Figure 1P ).
Cell Enrichment for NG2 by
Culture of kPSCs
1. Refresh the medium twice a week by removing half of the medium and replace it with freshly thawed culture medium ( Figure 1N) . NOTE: The kPSCs tend to be more viable and proliferative when only half of the medium is refreshed.
Passaging of kPSCs.
NOTE: Passage the kPSCs at either 90 -100% confluency, or when 3D structures appear (see Figure 1O ), or when there hasn't been cell growth for more than a week. The latter two particularly might occur at early passages after cell enrichment. In this case, after passaging, the cells will usually start to grow again in monolayer culture ( Figure 1P ). 1. Remove the medium from the 90 -100% confluent cells (keep the medium for later use). Wash the flask twice with PBS (1 mL in T25, 5 mL in T75, 10 mL in T175). Add trypsin (0.5 mL in T25, 2 mL in T75, 5 mL in T175) and incubate for 5 min at 37 °C. Add the old medium to the flask and resuspend gently. 2. Transfer to a 15 or 50 mL tube (depending on the volume) and centrifuge at 490 x g for 5 min. Count the viable cells and plate <250,000 in a T25, 250,000 -500,000 in a T75, or 700,000 -800,000 in a T175 (approximately 4 x 10 3 cells/cm 2 ).
3. Test the kPSCs at passage 5 or 6 (e.g., scratch assay, section 7). NOTE: Characterize the propagated cells by flow cytometry using standard protocols. Marker expression of NG2, PDGFR-β, CD146, CD73, CD90, CD105, HLA-ABC should all be positive and CD31, CD34, CD45 and HLA-DR should be negative. Test for mycoplasma, bacteria and fungi in the culture medium according to standard protocols of the clinical microbiology lab. Test the kPSCs functionally in a kidney epithelial wound scratch assay. Experiments are usually performed with sterile, flow cytometry-confirmed homogeneous kPSC populations with wound healing capacity between passage 6-8. 4. Cryopreserve the kPSCs by adding 0.5 mL cryopreservation medium to 0.5 mL cell suspension (2 million cells per mL of culture medium) using standard protocols. NOTE: After thawing, seed the kPSCs at a higher density (10 6 cells in a T175).
Representative Results
The clinical grade kPSCs isolation method is summarized in Figure 1 . Crude kidney cells are isolated from human transplant grade kidneys by collagenase perfusion. The resulting cell suspension is cultured until confluent in 5% platelet lysates. Then the perivascular stromal cell fraction is isolated based on NG2 expression.
kPSCs are plastic adherent spindle-shaped cells (Figure 2A) and are positive for the stromal markers CD73, CD90, CD105 and perivascular markers NG2, PDGFR-B and CD146, while negative for CD31, CD34, CD45 and HLA-DR ( Figure 2B) . Typically, a homogeneous population of kPSCs can be reached at passage 4 and kPSCs reach senescence around passage 9 -10 ( Figure 2C) . We therefore advise to perform experiments between passage 5 -8.
To evaluate the functional capacity of the isolated kPSCs, we perform an in vitro kidney epithelial wound scratch assay on every new batch of kPSCs, as we previously showed that the conditioned medium of kPSCs can accelerate epithelial wound healing in this scratch assay 15 . The kPSC conditioned medium is made by culturing kPSCs for 48 h in alphaMEM 5% platelet lysates and collecting the supernatant. Next, the immortalized human kidney proximal tubule epithelial cells (HK-2) 17 are cultured until confluent and then a scratch wound is made. Then either the conditioned medium of kPSCs or control medium is added to the wells and the speed of wound healing is measured. When the conditioned medium of kPSCs is added, the wound closes significantly faster ( Figure 2D ). 
Discussion
Perivascular cells have been isolated from many different human solid organs, including pancreas, fat, cartilage and the kidney 9, 15, 16 . Most methods, however, are based on small samples of tissue, which are dissected and afterwards treated with digestive enzymes. Moreover, this is usually not performed with clinical grade products. This makes these strategies less suitable for direct clinical translation where large quantities of clinical-grade cells are necessary.
Here we show a novel isolation method of human kPSCs for whole organs based on perfusion with clinical grade enzymes and materials. The protocol is adapted from the clinical islets of Langerhans isolation protocol currently in use for clinical application in our center 18 . This is the first clinical grade method where large quantities of kPSCs can be achieved. The variability in cell yield is largely donor dependent. However, when the cell yield we currently obtain from a fraction of the crude cell suspension of three different donors is extrapolated, in theory, an average yield of 2.7 x 10 12 kPSCs per donor could be achieved. As MSC therapy typically consists of 2 cell infusions with 1 -2 x 10 6 cells/kg body weight 4 , these cell numbers are sufficient for allogenic treatment of several patients.
One critical step in the isolation procedure is the duration of collagenase digestion. When the digestion period is too short, large clumps of tissue will remain, which will be harder to culture. When the perfusion period is too long, increased cell death may be observed. Therefore, as soon as the kidney starts to become soft and the fluids less transparent, the kidney should be massaged gently and the collagenase treatment should be stopped.
Another critical step is the culture of the cells after NG2 cell enrichment. Sometimes after the NG2 cell enrichment, the perivascular cells do not start to proliferate or start to grow in 3D structures. In this case, when the cells are trypsinized and reseeded, the cells will usually start to grow in monolayer culture.
, cell therapy with kPSCs in kidney diseases and transplantation would be an interesting future application. For this purpose, there are several strategies of cell/cell product delivery. The first strategy is IV infusion of kPSCs, as used currently in the bmMSC clinical studies. Another interesting application is the use of kPSCs or kPSC-excreted factors in machine perfusion before transplantation. In this way, the quality of the explanted kidney might improve which could lead to improved kidney function after transplantation. For both strategies, kPSCs are an interesting new cell source to further explore for clinical purposes.
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